Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease
Journal of Clinical Investigation · 02.11.2026 · 136 (21)
DOI: 10.1172/jci205416 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.11.2026. Verfasst von Pasquale Mone und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy. Hauptthemen laut MEDLINE: Hypertension, Benzhydryl Compounds, Glucosides, Renal Insufficiency, Chronic. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
BACKGROUND Chronic kidney disease (CKD) and hypertension share common pathophysiological pathways contributing to vascular damage, endothelial dysfunction, and physical decline, particularly in older adults with prefrailty. To evaluate the relationship among renal injury, physical performance, and frailty progression in hypertensive older adults with CKD and assess whether dapagliflozin associates with reduced frailty progression, we designed the study DAPA-FORTRESS (DAPAgliflozin and Frailty prOgression in hypeRTension and chRonic kidnEy diSeaSe). METHODS We enrolled 135 prefrail hypertensive patients with CKD aged >65 years and followed them for 1 year. After coarsened exact matching, our balanced cohort had 105 patients (52 dapagliflozin). Associations between albuminuria, estimated glomerular filtration rate (eGFR), and physical performance were analyzed using correlation and regression models. Effect of dapagliflozin on frailty progression was evaluated using multivariable logistic regression. RESULTS A significant inverse association between gait speed and albuminuria ( r 2 = 0.48, P < 0.0001) and significant positive linear association between gait speed and eGFR ( r 2 = 0.18; P < 0.0001) were observed. Patients with eGFR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.
- Clinica Montevergine, GVM Care and Research, Mercogliano (Avellino), Italy.
- Division of Internal Medicine, Veneziale Hospital, Isernia, Italy.
- Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
- Local Health Unit of the Italian Ministry of Health (ASL), Avellino, Italy.
- Department of Medicine, Surgery, and Dentistry, "Scuola Medica Salernitana", University of Salerno, Baronissi (Salerno), Italy.
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Mone, P., Viggiano, D., Pansini, A., Soldovieri, M. V., Sabatelli, G., Visco, V., Macina, G., Boccalone, E., Ciccarelli, M., Martinelli, G., Di Mauro, M., Vecchione, C., Morgante, M., Varzideh, F., Guerra, G., & Santulli, G. (2026). Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease. Journal of Clinical Investigation, 136(21). https://doi.org/10.1172/jci205416
Vancouver
Mone P, Viggiano D, Pansini A, Soldovieri MV, Sabatelli G, Visco V, et al. Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease. Journal of Clinical Investigation. 2026;136(21). doi:10.1172/jci205416
BibTeX
@article{Mone2026,
author = {Mone, Pasquale and Viggiano, Davide and Pansini, Antonella and Soldovieri, Maria Virginia and Sabatelli, Giada and Visco, Valeria and Macina, Gaetano and Boccalone, Eugenio and Ciccarelli, Michele and Martinelli, Giuseppe and Di Mauro, Marco and Vecchione, Carmine and Morgante, Maria and Varzideh, Fahimeh and Guerra, Germano and Santulli, Gaetano},
title = {Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {21},
doi = {10.1172/jci205416}
}
EUVIMED